- Appetite-suppressing drugs are causing investor concern, and rapid weight loss is creating a new product market.
- Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.
Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.
1 report, 1 independent
Updated Sep 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
Nothing else this week.